Thermo Fisher Scientific (Waltham, Massachusetts, USA) has announced the acquisition of global clinical research and laboratory service provider, PPD (Wilmington, North Carolina, USA). The acquisition was first announced in April, with Thermo Fisher agreeing to purchase PPD for $47.50 per share, a total of $17.4 billion, plus the assumption of around $3.5 billion of net debt.
Speaking back in April, David Simmons, Chairman and Chief Executive Officer, PPD, said, “Thermo Fisher is a world‑class company with a very similar culture and values and will provide a great foundation for our colleagues to continue to deliver for our customers and to develop their own skills and careers.”
PPD has more than 26,000 employees operating across 50 countries, and it produced revenue of $4.7 billion in 2020. Following the transaction, PPD has now become part of Thermo Fisher’s Laboratory Products and Services Segment.
“We are very excited to officially welcome our PPD colleagues to Thermo Fisher Scientific,” said Thermo Fisher Chairman, President, and CEO Marc N. Casper. “Expanding our value proposition for our biotech and pharmaceutical customers with the addition of PPD’s leading clinical research services advances our work in bringing life-changing therapies to market, benefitting patients around the world.”
For more information, please visit: www.thermofisher.com
Detailed Glycosylation Analysis of Therapeutic Enzymes Utilizing Comprehensive 2D-LC–MS
January 3rd 2025In this article, the use of comprehensive two-dimensional liquid chromatography (LC×LC) coupled to mass spectrometry (MS) for characterizing glycosylation of therapeutic enzymes is presented.
Advancing Gene Therapy: Enzyme Selection for Effective RNA Oligonucleotide Mapping
New gene therapy modalities, such as CRISPR guide RNA (single guide ribonucleic acid [sgRNA]) and messenger RNA (mRNA), continue to make progress in both primate and first-in-human trials. As this progress builds, the industry remains accountable for characterizing these molecules to meet the requirements of regulatory authorities.